10X Genomics Inc - Asset Resilience Ratio
10X Genomics Inc (TXG) has an Asset Resilience Ratio of 4.81% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 10X Genomics Inc (TXG) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how 10X Genomics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of 10X Genomics Inc.
Liquid Assets Composition Over Time
This chart breaks down 10X Genomics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 10X Genomics Inc (TXG) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $49.52 Million | 4.81% |
| Total Liquid Assets | $49.52 Million | 4.81% |
Asset Resilience Insights
- Limited Liquidity: 10X Genomics Inc maintains only 4.81% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
10X Genomics Inc Industry Peers by Asset Resilience Ratio
Compare 10X Genomics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Vitrolife AB
ST:VITR |
Medical Devices | 7.27% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 12.10% |
|
Imricor Medical Systems Inc
AU:IMR |
Medical Devices | 46.50% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
Annual Asset Resilience Ratio for 10X Genomics Inc (2017–2025)
The table below shows the annual Asset Resilience Ratio data for 10X Genomics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.75% | $49.44 Million | $1.04 Billion | -0.62pp |
| 2024-12-31 | 5.37% | $49.34 Million | $918.64 Million | +2.32pp |
| 2023-12-31 | 3.05% | $29.41 Million | $965.14 Million | -17.38pp |
| 2022-12-31 | 20.43% | $210.24 Million | $1.03 Billion | -- |
| 2021-12-31 | 0.00% | $0.00 | $1.02 Billion | -- |
| 2018-12-31 | 0.00% | $0.00 | $124.31 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $75.61 Million | -- |
About 10X Genomics Inc
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related… Read more